Scopus
YÖKSİS ISSN Eşleşti
SJR Q1
Recovery of abnormal ejaculation by intermittent tamsulosin treatment
Journal of Urology · Ocak 2006
Özet
Purpose: We assessed the impact of intermittent tamsulosin treatment on abnormal ejaculation. Materials and Methods: This prospective study was performed between January 2001 and December 2004. It included 405 patients who were at least 50 years old with lower urinary tract symptoms. This study was divided into 2 phases. In phase 1 patients received a 0.4 mg tamsulosin capsule daily after breakfast for at least 3 months. The second phase of this study was performed in the 30 patients with abnormal ejaculation. In this phase these patients received 0.4 mg tamsulosin once daily every other day. Patients were assessed at study entry and at study week 6. Results: Abnormal ejaculation was reported as retrograde ejaculation by 18 patients, as decreased volume by 7 and as absent ejaculate by 5. Ejaculatory function recovered during intermittent tamsulosin treatment in 12 patients with retrograde ejaculation and in 7 with decreased volume or absent ejaculate. As a result, 19 of 30 patients (63.3%) with abnormal ejaculation recovered. A significant improvement in retrograde ejaculation was found after intermittent tamsulosin treatment (p = 0.02). Although there were improvements in decreased volume or absent ejaculate at week 6 of intermittent treatment, these differences were not statistically significant (p = 0.42 and 0.61, respectively). Conclusions: The results of the current study, which to our knowledge is the first report of the effect of intermittent tamsulosin treatment on abnormal ejaculation, show that this treatment modality is well tolerated and provides comparable improvements for abnormal ejaculation. Copyright © 2006 by American Urological Association.
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 3 kaydı bulundu.
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 3 kaydı bulundu.
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
2024 ISSN: 0022-5347 SCI-Expanded Q1
Doç. Dr. MURAT GÜL →
Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
2024 ISSN: 0022-5347 SCI-Expanded Q1
Doç. Dr. EMRE ALTINTAŞ →
Letter: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
2024 ISSN: 0022-5347 SCI-Expanded Q1
Doç. Dr. ALİ FURKAN BATUR →
Makale Bilgileri
Dergi
Journal of Urology
Toplam Atıf
26 atıf
· Scopus
ISSN00225347
Yayın TarihiOcak 2006
Cilt / Sayfa175 · 650-653
Scopus ID2-s2.0-30344443396
Kurumlar
Gülhane Eğitim ve Araştırma Hastanesi
Ankara Turkey
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 26.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi (ISSN Eşleşmesi)
Journal of Urology
Q1
OA
SJR Skoru2,192
H-Index299
YayıncıWolters Kluwer Health
ÜlkeUnited Kingdom
Urology (Q1)
Metrikler
26
Atıf